Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Likely To Take Holistic View Of AER Bill Compliance, Expert Says

This article was originally published in The Tan Sheet

Executive Summary

FDA will likely evaluate a company's compliance with adverse event reporting and record-keeping requirements on a "performance-oriented basis," said Rick Kingston, PharmD, president and senior clinical toxicologist at SafetyCall International, an adverse event call center

You may also be interested in...



Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar

The implementation of the adverse event reporting bill will present the dietary supplement and nonprescription drug industries with challenges as well as opportunities, experts stressed at a recent United Natural Products Alliance seminar on the implementation of the new law

Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar

The implementation of the adverse event reporting bill will present the dietary supplement and nonprescription drug industries with challenges as well as opportunities, experts stressed at a recent United Natural Products Alliance seminar on the implementation of the new law

Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar

The implementation of the adverse event reporting bill will present the dietary supplement and nonprescription drug industries with challenges as well as opportunities, experts stressed at a recent United Natural Products Alliance seminar on the implementation of the new law

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel